Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Humedix Co., Ltd. (200670:KRX), powered by AI.
Humedix Co., Ltd. is currently trading at ₩28,800. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Humedix Co., Ltd. on Alpha Lenz.
Humedix Co., Ltd.'s P/E ratio is 6.1.
“Humedix Co., Ltd. trades at a P/E of 6.1 (undervalued) with strong ROE of 19.6%. 3Y revenue CAGR of 11.3% highlights clear growth momentum.”
Ask for details →Humedix Co., Ltd. is a promising biopharmaceutical company primarily focused on the development, production, and distribution of medical and healthcare products. This South Korean firm has carved out a niche in the global market by specializing in aesthetic and therapeutic solutions, particularly pioneering advancements in dermal fillers and hyaluronate-based pharmaceuticals. Its portfolio prominently features items aimed at enhancing skin health and medical devices utilised in plastic surgery and ophthalmology. Humedix plays a crucial role in the healthcare sector, contributing to both the enhancement of medical treatments and aesthetic procedures. Its innovative products have gained significant traction, fostering a reputation for quality and effectiveness in the medical community. The company’s commitment to research and development underpins its status in the pharmaceutical industry, aiming to bring about positive health outcomes and improved quality of life for patients. As a key player in the regional market, Humedix Co., Ltd. continues to expand its influence, driving both industry growth and innovation in medical technology.
“Humedix Co., Ltd. trades at a P/E of 6.1 (undervalued) with strong ROE of 19.6%. 3Y revenue CAGR of 11.3% highlights clear growth momentum.”
Ask for details →Humedix Co., Ltd. (ticker: 200670) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $317.8B.
The current price is ₩28,800 with a P/E ratio of 6.14x and P/B of 1.06x.
ROE is 19.61% and operating margin is 24.89%. Annual revenue is $170.1B.